Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 10/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 10/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.47 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.45 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | GNRHR | P30968 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688688 | 0.82 | OPRM1 (0.51) | NTSR2NTSR1SORT1NPY1R | |
| SCHEMBL30423100 | 0.82 | APLNR (0.45) | APLNRNTSR2NTSR1NMUR2NMUR1 | |
| SCHEMBL30585577 | 0.80 | OPRM1 (0.48) | NMUR2NMUR1GNRHRNPY1R | |
| SCHEMBL29914692 | 0.79 | OPRM1 (0.50) | APLNRNTSR2NTSR1NPY1R | |
| SCHEMBL29611526 | 0.79 | APLNR (0.48) | APLNRNTSR2NTSR1NMUR2NMUR1 | |
| SCHEMBL30345087 | 0.78 | OPRM1 (0.53) | APLNRNTSR2NTSR1NMUR2NMUR1 | |
| SCHEMBL31590961 | 0.78 | OPRM1 (0.53) | APLNRNTSR2NTSR1NMUR2NMUR1 | |
| SCHEMBL29615168 | 0.78 | GNRHR (0.45) | APLNRNTSR2NTSR1GNRHR | |
| SCHEMBL29383471 | 0.78 | GNRHR (0.45) | APLNRNTSR2NTSR1GNRHR | |
| SCHEMBL8773027 | 0.77 | APLNR (0.43) | APLNRNTSR2NTSR1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023101490-A1 | NOVEL METHOD FOR MANUFACTURING GANIRELIX | 애니젠 주식회사 | 2023-06-08 | — | — | WO | disclosed |